151, ISBN 83-7183-240-0, OCLC 749698778
Harding's original studies report a dramatic increase in dendritic density in the hippocampus and memory restoration in rodent models of cholinergic lesion (scopolamine, 192-IgG-saporin)
late 2027 or early 2028 later than the 2027 window implied by Lilly's earlier "submit in 2026" guidance
Program pricing depends on medication, dosage, treatment duration, and insurance coverage
In summary, the 15 mg dose offers the strongest average therapeutic effect, but many patients achieve excellent results on middle doses (5 mg or 10 mg)
(Or indeed any surprising foods or vitamins that interact with attention?) If not, could someone develop molecules that achieve the goals we really care about with respect to attention, better than whats on offer